For the past 5 years, neuropathologists have been applying 2016 WHO classification to the diagnosis of CNS tumors; thus, it is necessary to add EPN-RELA fusion-positive to ST-EPN-ZFTA fusion-positive. This evidence concerns the gene MME and central nervous system neoplasm.